Ascendis Pharma Gains Third Consecutive FDA Approval as YUVIWEL Launches in Rare Pediatric Indication

Ascendis Pharma's third consecutive FDA accelerated approval, this time for YUVIWEL (navepegritide) in achondroplasia, signals a repeatable regulatory execution model that QA and regulatory affairs teams across rare disease programs will be watching closely. The approval, combined with a Rare Pediatric Disease Priority Review Voucher sold for $187.5 million, illustrates how orphan drug designations are functioning as both clinical and commercial infrastructure in the current pipeline environment.

YUVIWEL received accelerated approval indicated to increase linear growth in children aged two and older with achondroplasia with open epiphyses, with orphan drug exclusivity running through February 27, 2033. As of May 1, 2026, more than 60 unique patient enrollments had been recorded across more than 35 prescribing healthcare providers since the U.S. commercial launch in April. A Marketing Authorisation Application remains under review by the European Medicines Agency, with a decision anticipated in Q4 2026.

For regulatory leads benchmarking accelerated approval timelines, the YUVIWEL pathway follows YORVIPATH (palopegteriparatide) and SKYTROFA (lonapegsomatropin) through the same TransCon platform, a prodrug technology designed to extend half-life and reduce dosing frequency. YORVIPATH posted Q1 2026 revenue of €197 million, with more than 1,000 new U.S. patient enrollments in the quarter and cumulative U.S. enrollments exceeding 6,300 across more than 2,700 prescribing providers. SKYTROFA contributed €44 million in Q1 revenue.

Pipeline activity relevant to manufacturing and process validation planning includes the ongoing reACHin label expansion trial in infants with achondroplasia, with enrollment completion anticipated in Q3 2026, and a Phase 3 trial in hypochondroplasia planned for the second half of the year. The Phase 2 COACH trial evaluating TransCon CNP plus TransCon hGH combination therapy reported Week 52 topline results showing mean annualized growth velocity exceeding the 97th percentile, with interim Week 78 data expected in Q2 2026.

YORVIPATH's Q1 revenue reflected normal seasonality, temporary free-drug patient support, and a one-time European impact tied to expanded market access, factors that plant heads managing demand forecasting and batch release schedules will need to account for as commercial volumes scale across 35 countries where the product is now available commercially or through named patient programs.

The Q4 2026 EMA decision on YUVIWEL will be the next measurable regulatory checkpoint for teams tracking the product's European manufacturing and distribution readiness.

Source: Ascendis Pharma A/S via GlobeNewswire, May 7, 2026. Conference call held at 8:00 am ET on the same date.